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Abstract
Background: The long-term prognosis of diabetic patients with acute myocardial infarction (AMI) treated by acute
revascularization is uncertain, and the optimal pharmacotherapy for such cases has not been fully evaluated.
Methods: To elucidate the long-term prognosis and prognostic factors in diabetic patients with AMI, a prospective,
cohort study involving 3021 consecutive AMI patients was conducted. All patients discharged alive from hospital
were followed to monitor their prognosis every year. The primary endpoint of the study was all-cause mortality,
and the secondary endpoint was the occurrence of major cardiovascular events. To elucidate the effect of various
factors on the long-term prognosis of AMI patients with diabetes, the patients were divided into two groups
matched by propensity scores and analyzed retrospectively.
Results: Diabetes was diagnosed in 1102 patients (36.5%). During the index hospitalization, coronary angioplasty
and coronary thrombolysis were performed in 58.1% and 16.3% of patients, respectively. In-hospital mortality of
diabetic patients with AMI was comparable to that of non-diabetic AMI patients (9.2% and 9.3%, respectively). In
total, 2736 patients (90.6%) were discharged alive and followed for a median of 4.2 years (follow-up rate, 96.0%).
The long-term survival rate was worse in the diabetic group than in the non-diabetic group, but not significantly
different (hazard ratio, 1.20 [0.97-1.49], p = 0.09). On the other hand, AMI patients with diabetes showed a
significantly higher incidence of cardiovascular events than the non-diabetic group (1.40 [1.20-1.64], p < 0.0001).
Multivariate analysis revealed that three factors were significantly associated with favorable late outcomes in
diabetic AMI patients: acute revascularization (HR, 0.62); prescribing aspirin (HR, 0.27); and prescribing renin-
angiotensin system (RAS) inhibitors (HR, 0.53). There was no significant correlation between late outcome and
prescription of beta-blockers (HR, 0.97) or calcium channel blockers (HR, 1.27). Although standard Japanese-
approved doses of statins were associated with favorable outcome in AMI patients with diabetes, this was not
statistically significant (0.67 [0.39-1.06], p = 0.11).
Conclusions: Although diabetic patients with AMI have more frequent adverse events than non-diabetic patients
with AMI, the present results suggest that acute revascularization and standard therapy with aspirin and RAS
inhibitors may improve their prognosis.
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Treatment of coronary artery disease (CAD) has pro-
gressed rapidly since the introduction of coronary artery
bypass grafting (CABG) and percutaneous coronary
intervention (PCI). The introduction of antiplatelet
agents, angiotensin-converting enzyme inhibitors
(ACEIs), and statins has also led to marked changes in
the medical management of CAD. Several large-scale
clinical studies have been conducted to verify the effi-
cacy of these therapies, and guidelines for the treatment
of CAD have been established by medical societies
based on the results of these studies [1]. Previous stu-
dies[2,3] clearly demonstrated that diabetic patients with
CAD have a poor prognosis. However, the long-term
prognosis of diabetic patients with acute myocardial
infarction (AMI) is uncertain, and optimal pharma-
cotherapy has not been established in the contemporary
acute revascularization era.
To assess the current management of AMI in Japan
and the prognosis of Japanese patients, we conducted a
prospective cohort study (The Heart Institute of Japan,
Acute Myocardial Infarction registry: HIJAMI), in which
consecutive patients with AMI who were admitted to
the Department of Cardiology at The Heart Institute of
Japan (Tokyo Women’s Medical University) and related
institutions were enrolled and followed [4]. Of the
patients enrolled in the HIJAMI registry, those with dia-
betes mellitus were selected for the present, prospective,
observational study designed to assess the clinical status
of such patients, therapeutic modalities, and their prog-
nosis, in order to determine the optimal therapeutic
management of diabetic patients with AMI.
Methods
Study sample
Full details of the HIJAMI registry have been described
previously[4]. In brief, HIJAMI is a multicenter, prospec-
tive cohort of consecutive patients with AMI who were
admitted within 48 hours after the onset of symptoms.
Between January 1999 and June 2001, 3021 consecutive
patients from 17 participating hospitals in Japan were
registered. As HIJAMI was meant for observational pur-
poses, treatment strategies, such as drug therapies and
early reperfusion treatment, were used at the discretion of
the physician responsible at each hospital. Clinical and
angiographic data, including the patients’ demographics,
coronary risk factors, therapeutic modalities, complica-
tions, number of diseased vessels, infarct-related arteries,
PCI strategies, laboratory data, and outcomes were pro-
spectively collected using a standardized case report form.
AMI was diagnosed on the basis of the following criteria:
(1) typical chest pain; (2) a greater than two-fold elevation
of cardiac muscle enzyme levels compared to normal
levels; and (3) new appearance of abnormal Q waves, an
elevation or reduction of ST segments, a typical change in
T waves, or new appearance of left bundle branch block
[5]. When at least two of the above three criteria were met,
AMI was diagnosed. All patients discharged alive from
hospital were followed to monitor their prognosis every
year (in December) by review of their medical records or
telephone survey. The study was conducted according to
the Declaration of Helsinki and was approved by the ethi-
cal review board of each institution. At the time of enroll-
ment, informed consent for participation in the study was
obtained either in writing or orally from all subjects.
Diabetes mellitus was diagnosed according to the fol-
lowing criteria[6]: a prior diagnosis of diabetes in a
patient receiving antidiabetic treatment, or a fasting
blood glucose level ≥ 126 mg/dl, a blood glucose level
higher than 200 mg/dL 2 hours after the 75 g OGTT,
or a random blood glucose level ≥ 200 mg/dl on two or
more occasions, or these standard values were exceeded
once and any of the following criteria were met (i: typi-
cal symptoms (dry mouth, polydipsia, polyuria, and
weight loss), ii: HbA1c ≥ 6.5%, or iii: presence of diabetic
retinopathy). Hypertension was diagnosed when the
patient had a history of hypertension or had a systolic
blood pressure ≥ 140 mmHg or a diastolic blood pres-
sure ≥ 90 mmHg during index hospitalization. Hyperch-
olesterolemia was diagnosed when the patient had a
history of dyslipidemia or a fasting total cholesterol level
≥ 220 mg/dl or a fasting triglyceride level ≥ 150 mg/dl.
Follow-up
The primary endpoint of the study was the all-cause
mortality rate, and the secondary endpoint was the
occurrence of major cardiovascular events (including
death from cardiovascular causes, recurrent myocardial
infarction, unstable angina or heart failure requiring
hospitalization, and coronary revascularization).
Two studies were performed. First, the long-term
prognosis after myocardial infarction was compared
between diabetic and non-diabetic patients. The patients
were classified into a diabetic group with AMI and a
non-diabetic group with AMI, and the primary and sec-
ondary endpoints were compared over the long term.
Second, the effects of various therapies on life expec-
tancy after myocardial infarction were assessed. To
study the therapeutic modalities that affected life expec-
tancy in diabetic patients with AMI, PCI in the acute
phase and the drugs prescribed at discharge (aspirin,
beta-blockers, calcium antagonists, nitrates, ACEIs,
angiotensin receptor agonists (ARBs), and statins) were
evaluated in diabetic patients with AMI. To balance
observed covariates between the two groups, the pro-
pensity score method was used[7].
This study was funded by the Japan Research Promo-
tion Society for Cardiovascular Diseases, which played
no role in the conduct of the study.
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Continuous variables showing a normal distribution are
expressed as the mean and standard deviation. Data
without a normal distribution are expressed as the med-
ian and interquartile range (IQR) (25%, 75%). Compari-
sons between the two groups were done using Student’s
t-test for data assumed to have a normal distribution,
the Mann-Whitney U-test for data without a normal
distribution or for ordered, categorical data, and the chi-
square test for non-ordered, categorical data. All statisti-
cal tests were two-sided, and the level of significance
was set at p = 0.05. Since this was a prospective obser-
vational study and not a comparative study using rando-
mization, even the diabetic patients with AMI showed
some differences in background factors. Therefore, the
hazard ratio (HR) and its 95% confidence interval (CI)
were calculated using multiple logistic regression after
propensity scores were used to match subjects for the
20 factors mentioned below. Diabetic patients with AMI
were divided into two groups according to use or non-
use of each therapy, and patients with matched propen-
sity scores were extracted to examine associations with
life expectancy. For the calculation of propensity scores,
age, sex, severity of heart failure at admission, history of
hypertension, history of hypercholesterolemia, smoking
habits, history of myocardial infarction, PCI at admis-
sion, left ventricular ejection fraction, number of ste-
nosed coronary vessels, time from onset of AMI to
revascularization, HbA1c, C-reactive protein, serum crea-
tinine, and medications prescribed at the time of dis-
charge from hospital (aspirin, ACEIs, or angiotensin
receptor blockers (ARBs), calcium antagonists, nitrates,
and statins) were used, and then propensity scores were
calculated using a multiple logistic regression model
[7,8]. The cumulative probabilities of event curves were
estimated using the Kaplan-Meier method. To evaluate
the effect of therapeutic modalities with respect to sub-
sequent events, conventional Cox proportional hazards
models were used. Statistical analysis was performed
with SAS software version 9.1 (SAS Institute, Cary, NC,
USA).
Results
Baseline characteristics
A total of 3021 consecutive patients with AMI was
enrolled between January 1999 and June 2001. There
were 2136 men (70.7%) and 885 women (29.3%); their
average age was 69 years. Of these patients, 1102
(36.5%) had diabetes mellitus. Their average age was 66
years, 73% of them were men, and they more often had
a history of hypertension, hypercholesterolemia, or myo-
cardial infarction than the non-diabetic patients. Also,
congestive heart failure was more common in the acute
phase, and a higher percentage of patients had a
reduced left ventricular ejection fraction and multi-ves-
sel coronary artery disease in the chronic phase. There
were no significant differences between the diabetic and
non-diabetic patients with respect to CRP and renal
function. During the index hospitalization, successful
revascularization was achieved in 71.5% of the AMI
patients with diabetes and in 77.5% of the AMI patients
without diabetes. The overall death rate was 9.3% for
the diabetic group and 9.2% for the non-diabetic group
during index hospitalization (Table 1).
Long-term follow-up
A total of 2,736 patients was discharged alive and fol-
lowed regularly. The average duration of follow-up for
assessment of the prognosis was 4.2 years (0.0027 to 6.4
years), and the follow-up rate was 96%. In the HIJAMI
study, the follow-up assessment was conducted by a tel-
ephone survey in 31.8% (with a response rate of 94.3%).
Of the patients who were discharged alive, 1,000 were
diabetic (Table 2). Although the long-term survival rate
was worse in the diabetic group than in the non-diabetic
group, the difference in rates was not significant (HR =
1.20, 95% C. I.:0.97-1.49, p = 0.09, Figure 1). The causes
of death in the diabetic group were cardiac (7.2%),
including heart failure (3.0%), myocardial infarction
(2.1%), and other cardiac deaths (2.1%), cerebrovascular
disease (1.2%), malignancy (1.8%), and other conditions
(5.2%). In the non-diabetic group, the causes of death
were cardiac (4.6%), including heart failure (2.0%), myo-
cardial infarction (0.8%), and other cardiac deaths
(1.8%), cerebrovascular disease (0.9%), malignancy
(1.8%), and other conditions (4.3%). The diabetic group
showed a significantly higher incidence of cardiovascular
events than the non-diabetic group (1.40 [1.20-1.64],
p < 0.0001, Figure 2).
Prognostic factors associated with long-term survival
Aspirin was prescribed at discharge to 1,550 (89%) of
the 1,736 non-diabetic AMI patients, and 881 (88%) of
the 1,000 diabetic AMI patients. ACEIs and ARBs were
also prescribed at relatively high rates (63%) in both
groups. However, b-blockers, calcium antagonists, and
nitrates were prescribed at higher rates in the diabetic
group (Table 2).
To elucidate factors with an effect on the long-term
prognosis of the diabetic patients with AMI, propensity
scores were calculated. Diabetic patients with AMI were
divided into two groups according to use or non-use of
Table 1 Interventional Methods and In-hospital Mortality
PCI
n (%)
CT
n (%)
CABG
n (%)
Mortality
(%)
Diabetic 612 (55.5) 168 (15.2) 9 (0.8) 9.3
Nondiabetic 1140 (59.7) 322 (16.9) 18 (0.9) 9.2
CABG: Coronary artery bypass grafting. CT: Coronary thrombolysis. PCI:
Percutaneous coronary intervention.
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scores were extracted to examine associations with life
expectancy. Use of an ACEI or ARB at discharge was
significantly related to a better long-term prognosis for
diabetic patients with AMI (0.53 [0.36-0.76], p = 0.001).
Similarly, use of aspirin at discharge was significantly
associated with a good long-term prognosis (0.27 [0.15-
0.50], p < 0.0001). In contrast, use of beta-blockers (0.97
[0.67-1.42], p = 0.889), calcium antagonists (1.27 [0.88-
1.85], p = 0.205), and nitrates (0.96 [0.61-1.53], p =
0 . 8 7 4 )w a sn o ta s s o c i a t e dw i t h prognosis. Doses of sta-
tins based on the standard, approved Japanese doses
were associated with improved prognosis in AMI
patients with diabetes, but not significantly (0.67 [0.39-
1.06], p = 0.11). On the other hand, a significant asso-
ciation was found between successful PCI during the
acute phase and a favorable long-term prognosis (0.52
[0.36-0.74], p = 0.02; Figure 3).
Discussion
Observation of the long-term prognosis of AMI patients
has shown that acute revascularization and treatment with
ACEIs, ARBs, and aspirin are likely to improve life expec-
tancy, even in diabetic patients with myocardial infarction.
An increase in diabetes mellitus, which is associated
with global adoption of a Western lifestyle, has become
a worldwide problem[9]. The prevalence of coronary
artery disease in diabetic patients is reported to be two
to four times higher than in non-diabetic patients[10].
The effect of diabetes on secondary prevention in AMI
patients in the contemporary acute revascularization era
is unclear. Although the in-hospital survival rate of AMI
patients with diabetes is comparable to that of non-dia-
betic AMI patients, diabetic patients with AMI were
found to have a higher long-term death rate and a sig-
nificantly higher incidence of cardiovascular events than
non-diabetic patients with AMI.
Early revascularization of the culprit vessel is recog-
nized as a particularly important prognostic factor in
patients with AMI. However, the coronary artery disease
of diabetic patients tend to be diffuse and involve multi-
ple vessels, as well as being associated with calcification
and coronary artery remodeling, so that vessel diameters
are reduced, and achieving revascularization or reperfu-
sion is often quite difficult[11]. Diabetes mellitus remains
an independent predictor of adverse events after PCI
despite advances in interventional techniques and equip-
ment, as well as use of adjunctive pharmacotherapy.
Indeed, diabetes mellitus was associated with adverse
events after PCI in a recent clinical trial [12]. However,
the investigators also demonstrated that the effect of dia-
betes on angiographic restenosis appeared to be less
striking than estimated previously. Furthermore, hyper-
glycemia enhances platelet aggregation and smooth mus-
cle cell proliferation, so that restenosis is more likely to
occur. The BARI study was conducted in diabetic
patients with multi-vessel coronary artery disease who
received PCI or CABG. Long-term follow-up of these
patients revealed that there was a significantly higher
incidence of cardiac death among patients treated with
PCI than among patients receiving CABG[13]. However,
a number of important devices have been developed
since the BARI study was conducted. This means that
the results of PCI have improved dramatically, so that the
difference in outcome between CABG and PCI has
decreased. In fact, some studies have shown a better
long-term prognosis with PCI than CABG, since it can
shorten the time from the onset of stenosis until reperfu-
sion in seriously ill patients with cardiogenic shock[14].
T h ee f f i c a c yo fa s p i r i nh a sb e e nd e m o n s t r a t e db ya
number of studies conducted in Western countries
[15,16]. In recent randomized trials in subjects with dia-
betes[17,18], the investigators failed to demonstrate that
Table 2 Patient characteristics
Non-Diabetic
(N = 1,736)
Diabetic
(N = 1,000)
P–Value
Age (years) 67 ± 13 66 ± 11 0.004
Men 1236 (71%) 726 (73%) 0.433
Killip class (%)
I 1530 (88%) 791 (79%) < 0.001
II 106 (6%) 85 (9%)
III 67 (4%) 85 (9%)
IV 33 (2%) 39 (4%)
Hypertension 901 (52%) 591 (59%) < 0.001
Hyperlipidemia* 624 (36%) 472 (47%) < 0.001
Smoking 944 (54%) 562 (56%) 0.356
Prior myocardial infarction 226 (13%) 188 (19%) < 0.001
Prior percutaneous
coronary intervention
131 (8%) 98 (10%) 0.040
Left ventricular ejection
fraction (%)
54 ± 13 51 ± 13 < 0.001
Number of diseased vessels
≤ 1 846 (49%) 390 (39%) <0.001
≥ 2 481 (28%) 322 (32%)
Undefined 409 (24%) 288 (29%)
Onset to reperfusion (hrs)** 4.5 [3.1-7.0] 4.6 [3.1-7.8] 0.881
HbA1c (%) 5.3 ± 0.5 7.1 ± 1.6 <0.001
C-reactive protein (mg/dl)** 0.3 [0.1-0.7] 0.3 [0.1-0.9] 0.027
Serum creatinine (mg/dl)** 0.8 [0.7-1.0] 0.9 [0.7-1.1] 0.048
Concomitant medications
Renin-angiotensin system
inhibitors
1095 (63%) 634 (63%) 0.866
b-blockers 522 (30%) 358 (36%) 0.002
Calcium antagonists 489 (28%) 356 (36%) < 0.001
Nitrates 1008 (58%) 669 (67%) < 0.001
Aspirin 1550 (89%) 881 (88%) 0.343
Plus minus values are mean ± S.D. *:Hyperlipidemia was defined as total
cholesterol > 220 mg/dl. **:Values are median [interquartile range]
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Page 4 of 7Figure 1 Kaplan-Meier survival curves for all-cause mortality among AMI patients with or without diabetes. The solid line indicates AMI
patients with diabetes; the dotted line indicates those without diabetes.
Figure 2 Kaplan-Meier curves for the time until the first occurrence of a major adverse cardiovascular event (MACE), consisting of
death from cardiovascular causes, recurrent myocardial infarction, angina pectoris or heart failure requiring hospitalization, and
coronary revascularization, among AMI patients with or without diabetes. The solid line indicates AMI patients with diabetes; the dotted
line indicates those without diabetes
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events as primary prevention. In the present study, use of
aspirin for secondary prevention was shown to be effec-
tive for diabetic patients with AMI. Large-scale, rando-
mized, controlled studies will be necessary to verify the
efficacy of aspirin in diabetic patients with AMI.
Diabetic patients with AMI showed an improved long-
term prognosis when they were treated with statins[19]
and beta-blockers[20]. Although we could not confirm
such a beneficial effect of statins and beta-blockers for dia-
betic patients with AMI in the present study, statins
showed a non-significant tendency to be effective. This
difference in outcomes may be explained by racial differ-
ences between Caucasians and Japanese, differences in the
pathology of hypercholesterolemia and hypertension, a
higher prevalence of coronary vasospasm among Japanese
patients[21], the lack of strict blood pressure and lipid
level targets in this observational study, and the use of
lower doses of these drugs in Japan compared with those
in clinical trials conducted in Europe and the USA[22].
The present study demonstrated that there is a signifi-
cant relationship between treatment with ACEIs and ARBs
and a favorable long-term prognosis. These drugs were
reported to block neurohumoral factors and to achieve sec-
ondary prevention by stabilizing arteriosclerotic lesions
[23,24]. The importance of the anti-inflammatory effect of
ARBs has also been pointed out, and this is likely to have
some effect on diabetic microangiopathy, in particular.
Study limitations
There are certain limitations in this retrospective analysis
o fd a t af r o map r o s p e c t i v ec o h o r ts t u d y .T h em a j o r
limitation of the current study is that it is based on a data-
driven post hoc analysis of a cohort study. Therefore, ther-
apeutic modalities were not allocated randomly. Although
the analysis of the effects of each therapeutic modality on
adverse event rates was performed with the powerful pro-
pensity score-matching technique, this control was limited
to variables for which data were available. In the present
study, the percentage of patients who were treated with
ACEIs or ARBs was higher than the percentage who were
treated with beta-blockers or statins. For this reason, no
significant differences were obtained by comparison,
which is inevitable in an observational study. Furthermore,
this study is not a clinical trial that targeted lipid-lowering.
Consequently, participants were treated with standard,
Japanese-approved doses of statins. Although statin ther-
apy showed a tendency to improve the prognosis of dia-
betic patients, a significant improvement was not shown
in the present study. We investigated the prognosis of dia-
betic patients with AMI but did not assess other coronary
risk factors that overlap with the components of the meta-
bolic syndrome in this analysis. As the HIJAMI was a data-
base constructed from cardiologists’ perspective, it
includes no details on diabetic complications, diabetes
duration, and type of diabetes. As the epidemiology of car-
diovascular disease in Japan is substantially different from
that of non-Japanese, one cannot simply assume that the
results of the present study can be extrapolated to non-
Japanese populations. In the future, randomized, con-
trolled studies should be conducted to elucidate the asso-
ciation of each risk factor with the prognosis of AMI
patients with diabetes.
Figure 3 Hazard ratio estimates and 95% CIs for all-cause mortality associated with therapeutic modalities on the long-term
prognosis in the diabetic patients with AMI.
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Although a significant relationship between the presence
of diabetes mellitus and in-hospital survival following AMI
was not observed in the contemporary acute revasculariza-
tion era, there was a significant association between dia-
betes and subsequent adverse events. Among diabetic
patients with AMI, early PCI and treatment with aspirin,
ACEIs, or ARBs were significantly associated with lower
long-term death rates. Thus, in diabetic patients with
AMI, acute revascularization should be attempted, as well
as treatment with aspirin and ACEIs or ARBs.
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